Literature DB >> 19136477

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Alexander Greenhough1, Helena J M Smartt, Amy E Moore, Heather R Roberts, Ann C Williams, Christos Paraskeva, Abderrahmane Kaidi.   

Abstract

It is widely accepted that alterations to cyclooxygenase-2 (COX-2) expression and the abundance of its enzymatic product prostaglandin E(2) (PGE(2)) have key roles in influencing the development of colorectal cancer. Deregulation of the COX-2/PGE(2) pathway appears to affect colorectal tumorigenesis via a number of distinct mechanisms: promoting tumour maintenance and progression, encouraging metastatic spread, and perhaps even participating in tumour initiation. Here, we review the role of COX-2/PGE(2) signalling in colorectal tumorigenesis and highlight its ability to influence the hallmarks of cancer--attributes defined by Hanahan and Weinberg as being requisite for tumorigenesis. In addition, we consider components of the COX-prostaglandin pathway emerging as important regulators of tumorigenesis; namely, the prostanoid (EP) receptors, 15-hydroxyprostaglandin dehydrogenase and the prostaglandin transporter. Finally, based on recent findings, we propose a model for the cellular adaptation to the hypoxic tumour microenvironment that encompasses the interplay between COX-2, hypoxia-inducible factor 1 and dynamic switches in beta-catenin function that fine-tune signalling networks to meet the ever-changing demands of a tumour.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19136477     DOI: 10.1093/carcin/bgp014

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  463 in total

1.  Urinary prostaglandin E2 metabolite and risk for colorectal adenoma.

Authors:  Martha J Shrubsole; Qiuyin Cai; Wanqing Wen; Ginger Milne; Walter E Smalley; Zhi Chen; Reid M Ness; Wei Zheng
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-13

Review 2.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

3.  ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression.

Authors:  Sun-Hee Kim; Yun-Yong Park; Sang-Wook Kim; Ju-Seog Lee; Dingzhi Wang; Raymond N DuBois
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

4.  Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.

Authors:  Yanping Ding; Nan Song; Yongzhang Luo
Journal:  Cancer Microenviron       Date:  2012-04-20

5.  Oncoantigens for an immune prevention of cancer.

Authors:  Elisabetta Bolli; Elena Quaglino; Maddalena Arigoni; Pier-Luigi Lollini; Raffaele Calogero; Guido Forni; Federica Cavallo
Journal:  Am J Cancer Res       Date:  2010-12-20       Impact factor: 6.166

Review 6.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

7.  Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.

Authors:  Binglan Zhang; Xuelei Ma; Zhimian Li; Xiang Gao; Fengtian Wang; Lei Liu; Guobo Shen; Yaxiong Sang; Minmin Li; Yuli Li; Jingyi Zhao; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-06       Impact factor: 4.553

8.  Calcium/calmodulin-dependent protein kinase II regulates cyclooxygenase-2 expression and prostaglandin E2 production by activating cAMP-response element-binding protein in rat peritoneal macrophages.

Authors:  Xueyuan Zhou; Junying Li; Wenxiu Yang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

9.  Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-05-06       Impact factor: 3.466

10.  Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia.

Authors:  Clare Abbenhardt; Elizabeth M Poole; Richard J Kulmacz; Liren Xiao; Karen Curtin; Rachel L Galbraith; David Duggan; Li Hsu; Karen W Makar; Bette J Caan; Lisel Koepl; Robert W Owen; Dominique Scherer; Christopher S Carlson; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.